Historical records as far back as 3000 BCE show that oral and head and neck cancer was a disease process well known to Egyptian physicians. Luminaries such as Hippocrates, Galen, Pott, and Virchow were instrumental in shaping our understanding of the etiology and pathogenesis of cancer. During the 20th century, evidence-based medicine catalyzed the development of rigorous science-based diagnostic and treatment protocols. The use of surgery, therapeutic radiation, and chemotherapy as single-treatment agents or in combination with one another gradually emerged as the preferred approach to cancer therapy. The recognition of tobacco, alcohol, and human papillomavirus as etiological agents in oral and head and neck cancer prompted the development of new diagnostic aids and treatment strategies to mitigate cancer progression. More in-depth mechanistic insights into the multistep process of oral and head and neck cancer were made possible by the use of the hamster buccal pouch and mouse models. New technologies, such as the sequencing of the human genome, metabolomics, and proteomics, have provided the foundation for what we today call precision medicine. The future success of tailored medical treatment for cancer patients will depend on the discovery of new druggable targets with improved therapeutic efficacy. As the precision and sensitivity of existing tools for prevention and risk assessment improve, greater accuracy will be achieved in predicting health outcomes.
AckerknechtEH. 1958. Historical notes on cancer. Med Hist. 2(2):114–119.
2.
AgrawalNFrederickMJPickeringCRBettegowdaCChangKLiRJFakhryCXieTXZhangJWangJ, et al. 2011. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in notch1. Science (New York, NY). 333(6046):1154–1157.
3.
AllenJP, Metropolitan Museum of Art. 2005. The art of medicine in ancient Egypt. New York: Metropolitan Museum of Art.
4.
AngKKAndratschkeNHMilasL.2004. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 58(3):959–965.
5.
ArduinoPGSuraceACarboneMEliaAMassoliniGGandolfoSBroccolettiR.2009. Outcome of oral dysplasia: a retrospective hospital-based study of 207 patients with a long follow-up. J Oral Pathol Med. 38(6):540–544.
6.
BaisMVKukuruzinskaMTrackmanPC. 2015. Orthotopic non-metastatic and metastatic oral cancer mouse models. Oral Oncol. 51(5):476–482.
7.
BaliouSAdamakiMKyriakopoulosAMSpandidosDAPanayiotidisMChristodoulouIZoumpourlisV.2018. Crispr therapeutic tools for complex genetic disorders and cancer (review). Int J Oncol. 53(2):443–468.
8.
BaronUBujardH.2000. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol. 327:401–421.
9.
BaumlJSeiwertTYPfisterDGWordenFLiuSVGilbertJSabaNFWeissJWirthLSukariA, et al. 2017. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 35(14):1542–1549.
10.
BirkelandACOwenJHPrinceME. 2015. Targeting head and neck cancer stem cells: current advances and future challenges. J Dent Res. 94(11):1516–1523.
11.
BolosVGrego-BessaJde la PompaJL. 2007. Notch signaling in development and cancer. Endocr Rev. 28(3):339–363.
12.
BouquotJE. 1986. Common oral lesions found during a mass screening examination. J Am Dent Asso (1939). 112(1):50–57.
13.
BrunetJFDenizotFLucianiMFRoux-DossetoMSuzanMMatteiMGGolsteinP.1987. A new member of the immunoglobulin superfamily—CTLA-4. Nature. 328(6127):267–270.
14.
CastilhoRMSquarizeCHAlmeidaLO. 2017. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int J Mol Sci. 18(7). pii: E1506.
15.
ChangSSCalifanoJ.2008. Current status of biomarkers in head and neck cancer. J Surg Oncol. 97(8):640–643.
16.
ChiACDayTANevilleBW. 2015. Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA Cancer J Clin. 65(5):401–421.
17.
ChowkwanyunMBayerRGaleaS.2018. “Precision” public health—between novelty and hype. N Engl J Med. 379(15):1398–1400.
18.
ChungCHGuthrieVBMasicaDLTokheimCKangHRichmonJAgrawalNFakhryCQuonHSubramaniamRM, et al. 2015. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol. 26(6):1216–1223.
19.
ClinicalTrials.gov. 2011. Radiation therapy with cisplatin or cetuximab in treating patients with oropharyngeal cancer [accessed 2019 Mar 7]. http://clinicaltrials.gov/ct2/show/NCT01302834
20.
CognettiDMWeberRSLaiSY. 2008. Head and neck cancer: an evolving treatment paradigm. Cancer. 113(7 Suppl):1911–1932.
21.
CollinsFSVarmusH.2015. A new initiative on precision medicine. N Engl J Med. 372(9):793–795.
22.
D’SouzaWSaranathD.2015. Clinical implications of epigenetic regulation in oral cancer. Oral Oncol. 51(12):1061–1068.
23.
DeckerWKSafdarA.2009. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley’s legacy revisited. Cytokine Growth Factor Rev. 20(4):271–281.
24.
Del CampoJMHittRSebastianPCarracedoCLokanathaDBourhisJTemamSCupissolDDe RaucourtDMaroudiasN, et al. 2011. Effects of lapatinib monotherapy: results of a randomised phase ii study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 105(5):618–627.
25.
DippleAPigottMMoschelRCCostantinoN.1983. Evidence that binding of 7,12-dimethylbenz(a)anthracene to DNA in mouse embryo cell cultures results in extensive substitution of both adenine and guanine residues. Cancer Res. 43(9):4132–4135.
26.
DostFLe CaoKFordPJAdesCFarahCS. 2014. Malignant transformation of oral epithelial dysplasia: a real-world evaluation of histopathologic grading. Oral Surg Oral Med Oral Pathol Oral Radiol. 117(3):343–352.
27.
FeilRWagnerJMetzgerDChambonP.1997. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun. 237(3):752–757.
28.
FerrisRLBlumenscheinGJr.FayetteJGuigayJColevasADLicitraLHarringtonKKasperSVokesEEEvenC, et al. 2016. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375(19):1856–1867.
29.
FolzBJSilverCERinaldoAFaganJJPrattLWWeirNSeitzDFerlitoA.2008. An outline of the history of head and neck oncology. Oral Oncol. 44(1):2–9.
30.
The FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 356(19):1915–1927.
31.
GillisonMLKochWMCaponeRBSpaffordMWestraWHWuLZahurakMLDanielRWViglioneMSymerDE, et al. 2000. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 92(9):709–720.
32.
GorenchteinMPohCFSainiRGarnisC.2012. MicroRNAs in an oral cancer context—from basic biology to clinical utility. J Dent Res. 91(5):440–446.
33.
GuptaBJohnsonNWKumarN.2016. Global epidemiology of head and neck cancers: a continuing challenge. Oncology. 91(1):13–23.
34.
HanahanDWeinbergRA. 2011. Hallmarks of cancer: the next generation. Cell. 144(5):646–674.
35.
HarrisonLB. 1997. Applications of brachytherapy in head and neck cancer. Semin Surg Oncol. 13(3):177–184.
36.
HenryNLHayesDF. 2012. Cancer biomarkers. Mol Oncol. 6(2):140–146.
37.
IshidaKTomitaHNakashimaTHirataATanakaTShibataTHaraA.2017. Current mouse models of oral squamous cell carcinoma: genetic and chemically induced models. Oral Oncol. 73:16–20.
38.
JaffeeEMDangCVAgusDBAlexanderBMAndersonKCAshworthABarkerADBastaniRBhatiaSBluestoneJA, et al. 2017. Future cancer research priorities in the USA: a Lancet oncology commission. Lancet Oncol. 18(11):e653–e706.
39.
JiangWWFujiiHShiraiTMegaHTakagiM.2001. Accumulative increase of loss of heterozygosity from leukoplakia to foci of early cancerization in leukoplakia of the oral cavity. Cancer. 92(9):2349–2356.
40.
KangHKiessAChungCH. 2015. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 12(1):11–26.
41.
KaplanDHShankaranVDigheASStockertEAguetMOldLJSchreiberRD. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 95(13):7556–7561.
42.
KarabulutAReibelJTherkildsenMHPraetoriusFNielsenHWDabelsteenE.1995. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med. 24(5):198–200.
43.
KardinalCG. 1977. An outline of the history of cancer. Part I. Mo Med. 74(12):662–666.
44.
KelloffGJLippmanSMDannenbergAJSigmanCCPearceHLReidBJSzaboEJordanVCSpitzMRMillsGB, et al; AACR Task Force on Cancer Prevention. 2006. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer—a plan to move forward. Clin Cancer Res. 12(12): 3661–3697.
45.
KiesslingRKleinEProssHWigzellH.1975. “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse moloney leukemia cells: characteristics of the killer cell. Eur J Immunol. 5(2):117–121.
46.
KiesslingRKleinEWigzellH.1975. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse moloney leukemia cells: specificity and distribution according to genotype. Eur J Immunol. 5(2):112–117.
47.
KlempISteffenssenMBakholdtVThygesenTSorensenJA. 2016. Counseling is effective for smoking cessation in head and neck cancer patients—a systematic review and meta-analysis. J Oral Maxillofac Surg. 74(8):1687–1694.
48.
KoshizukaKHanazawaTFukumotoIKikkawaNOkamotoYSekiN.2017. The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma. J Hum Genet. 62(1):3–13.
49.
KrummelMFAllisonJP. 1995. Cd28 and ctla-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 182(2):459–465.
50.
LanglandsAO. 1982. Radiation therapy in the treatment of cancer: the past, the present, and the future. Aust N Z J Surg. 52(4):331–335.
51.
LingenMWAbtEAgrawalNChaturvediAKCohenED’SouzaGGurenlianJKalmarJRKerrARLambertPM, et al. 2017. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: a report of the American Dental Association. J Am Dent Assoc. 148(10):712–727.e710.
52.
LingenMWKalmarJRKarrisonTSpeightPM. 2008. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 44(1):10–22.
53.
LingenMWXiaoWSchmittAJiangBPickardRKreinbrinkPPerez-OrdonezBJordanRCGillisonML. 2013. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 49(1):1–8.
54.
MachielsJPHenrySZanettaSKaminskyMCMichouxNRommelDSchmitzSBompasEDilliesAFFaivreS, et al. 2010. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 28(1):21–28.
55.
MaoLLeeJSFanYHRoJYBatsakisJGLippmanSHittelmanWHongWK. 1996. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 2(6):682–685.
McGurkMGoodgerNM. 2000. Head and neck cancer and its treatment: historical review. Br J Oral Maxillofac Surg. 38(3):209–220.
58.
MehannaHMRattayTSmithJMcConkeyCC. 2009. Treatment and follow-up of oral dysplasia—a systematic review and meta-analysis. Head Neck. 31(12):1600–1609.
59.
MillerJFMitchellGFWeissNS. 1967. Cellular basis of the immunological defects in thymectomized mice. Nature. 214(5092):992–997.
60.
MincerHHColemanSAHopkinsKP. 1972. Observations on the clinical characteristics of oral lesions showing histologic epithelial dysplasia. Oral Surg Oral Med Oral Pathol. 33(3):389–399.
61.
MognettiBDi CarloFBertaGN. 2006. Animal models in oral cancer research. Oral Oncol. 42(5):448–460.
62.
MorrisAL. 1961. Factors influencing experimental carcinogensis in the hamster cheek pouch. J Dent Res. 40:3–15.
63.
MortonJJBirdGRefaeliYJimenoA.2016. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap. Cancer Res. 76(21):6153–6158.
64.
MoskovitzJMFerrisRL. 2018. Tumor immunology and immunotherapy for head and neck squamous cell carcinoma. J Dent Res. 97(6):622–626.
65.
NezelofC. 1994. European roots of pathology. Pathol Res Pract. 190(1):103–114.
66.
PanigrahiGBWalkerIG. 1990. The n2-guanine adduct but not the c8-guanine or n6-adenine adducts formed by 4-nitroquinoline 1-oxide blocks the 3′-5′ exonuclease action of t4 DNA polymerase. Biochemistry. 29(8):2122–2126.
67.
PignonJPBourhisJDomengeCDesigneL.2000. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Lancet. 355(9208):949–955.
68.
RazzoukS. 2014. Translational genomics and head and neck cancer: toward precision medicine. Clin Genet. 86(5):412–421.
69.
RedmondDEJr.1970. Tobacco and cancer: the first clinical report, 1761. N Engl J Med. 282(1):18–23.
70.
RogersLS. 1964. Cancer chemotherapy by continuous intra-arterial infusion: experience of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Infusion Study Group. Cancer. 17:1365–1380.
71.
RosinMPChengXPohCLamWLHuangYLovasJBereanKEpsteinJBPriddyRLeND, et al. 2000. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 6(2):357–362.
72.
RosinMPLamWLPohCLeNDLiRJZengTPriddyRZhangL.2002. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res. 62(22):6447–6450.
73.
SalahshourifarIVincent-ChongVKKallarakkalTGZainRB. 2014. Genomic DNA copy number alterations from precursor oral lesions to oral squamous cell carcinoma. Oral Oncol. 50(5):404–412.
74.
SalleyJJ. 1954. Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res. 33(2):253–262.
75.
SartorMADolinoyDCJonesTRColacinoJAPrinceMECareyTERozekLS. 2011. Genome-wide methylation and expression differences in HPV(+) and HPV(–) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics. 6(6):777–787.
76.
ShankaranVIkedaHBruceATWhiteJMSwansonPEOldLJSchreiberRD. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410(6832):1107–1111.
77.
ShinglerERoblesLAPerryRPenfoldCNessAThomasSAthene LaneJMartinRM. 2017. Tobacco and alcohol cessation or reduction interventions in people with oral dysplasia and head and neck cancer: systematic review protocol. Syst Rev. 6(1):161.
78.
ShiraiKO’BrienPE. 2007. Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol. 8(3):239–251.
79.
SimpleMSureshADasDKuriakoseMA. 2015. Cancer stem cells and field cancerization of oral squamous cell carcinoma. Oral Oncol. 51(7):643–651.
80.
SimpsonDRMellLKCohenEE. 2015. Targeting the Pi3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 51(4):291–298.
81.
SmithLPThomasGR. 2006. Animal models for the study of squamous cell carcinoma of the upper aerodigestive tract: a historical perspective with review of their utility and limitations. Part a. Chemically-induced de novo cancer, syngeneic animal models of HNSCC, animal models of transplanted xenogeneic human tumors. Int J Cancer. 118(9):2111–2122.
82.
SmithRAAndrewsKBrooksDDeSantisCEFedewaSALortet-TieulentJManassaram-BaptisteDBrawleyOWWenderRC.2016. Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 66(2):96–114.
83.
SnydermanRMeadeCDrakeC.2016. Value of personalized medicine. JAMA. 315(6):613.
84.
SpeightPMAbramTJFlorianoPNJamesRVickJThornhillMHMurdochCFreemanCHegartyAMD’ApiceK, et al. 2015. Interobserver agreement in dysplasia grading: toward an enhanced gold standard for clinical pathology trials. Oral Surg Oral Med Oral Pathol Oral Radiol. 120(4):474–482.e2.
85.
SpornMBDunlopNMNewtonDLSmithJM. 1976. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 35(6):1332–1338.
86.
SteinmanRMCohnZA. 1973. Identification of a novel cell type in peripheral lymphoid organs of mice: I. Morphology, quantitation, tissue distribution. J Exp Med. 137(5):1142–1162.
87.
StranskyNEgloffAMTwardADKosticADCibulskisKSivachenkoAKryukovGVLawrenceMSSougnezCMcKennaA, et al. 2011. The mutational landscape of head and neck squamous cell carcinoma. Science (New York, NY). 333(6046):1157–1160.
88.
SunSZhangZ.2016. Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization. Front Med. 10(1):104–110.
VokesEEWeichselbaumRR. 1990. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 8(5):911–934.
91.
WalshTLiuJLBrocklehurstPGlennyAMLingenMKerrAROgdenGWarnakulasuriyaSScullyC.2013. Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults. Cochrane Database Syst Rev. 11:CD010173.
92.
WatneAL. 1984. Treatment alternatives: head and neck cancers. Cancer. 54(11 Suppl):2673–2681.
93.
WilliamWNJrPapadimitrakopoulouVLeeJJMaoLCohenEELinHYGillenwaterAMMartinJWLingenMWBoyleJO, et al. 2016. Erlotinib and the risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial. JAMA Oncol. 2(2):209–216.
94.
WilliamsonSKMoonJHuangCHGuaglianonePPLeBlancMWolfGTUrbaSG. 2010. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol. 28(20):3330–3335.
95.
Wise-DraperTMDraperDJGutkindJSMolinoloAAWikenheiser-BrokampKAWellsSI. 2012. Future directions and treatment strategies for head and neck squamous cell carcinomas. Transl Res. 160(3):167–177.
YoungDXiaoCCMurphyBMooreMFakhryCDayA. 2015. Increase in head and neck cancer in younger patients due to human papillomavirus (HPV). Oral Oncol. 51(8):727–730
98.
ZafereoMEXuLDahlstromKRViamonteCAEl-NaggarAKWeiQLiGSturgisEM. 2016. Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus. Oral Oncol. 56:47–53.
99.
ZinkernagelRMDohertyPC. 1974. Restriction of in vitro T cell–mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 248(5450):701–702.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
